Urologic Oncology Research Symposium: "Immune Checkpoint Inhibitors: Impact of Macro and Microenvironment on Efficacy“ (2020)

Available on Friday, July 10

Rapid growth in the field of immune checkpoint inhibition has transformed treatment paradigms for genitourinary cancers, and the use of immunotherapy is under active investigation in almost all genitourinary malignancies and disease states. This webcast will provide opportunities for new knowledge about the tumor immune microenvironment of genitourinary tumors as well as host factors that may impact immune checkpoint (IC) response, and explore novel targets as well as non-IC immunotherapy modalities.

Registration Fees

Member Category


AUA MemberFree
AUA Non-Member$29.00

Target Audience

  • Physician scientists
  • Researchers
  • Clinical fellows
  • Postdoctoral fellows
  • Residents
  • Medical/graduate students

Course summary
Course opens: 
Course expires: 


Welcome and Opening Remarks

Peter Black, MD, FACS, FRCSC
University of British Columbia

William Kim, MD
University of North Carolina School of Medicine

Session One: Bladder Cancer

Moderator: David McConkey, PhD
Johns Hopkins Greenberg Bladder Cancer Institute

scRNAseq of urothelial cancer: comprehensive analysis of the tumor microenvironment

John P. Sfakianos, MD
Icahn School of Medicine at Mount Sinai

Role of the microenvironment in response to BCG treatment of bladder cancer

Robert Svatek, MD
University of Texas Health San Antonio (UTHSA)

FGFR3 Alterations Regulate the Tumor Immune Environment and Impact Response to Immunotherapy

Matthew D. Galsky, MD
Icahn School of Medicine at Mount Sinai

Session Two: Prostate Cancer

Moderator: Angelo De Marzo, MD, PhD
Johns Hopkins University

The Rise, Fall and Resurrection of PROSTVAC

James Gulley, MD, PhD
National Cancer Institute

Session Three: Kidney Cancer

Moderator: Brian Shuch, MD
University of California Los Angeles

Dissecting the Tumor Immune Microenvironment of Clear Cell Renal Cell Carcinoma

Yousef Zakharia, MD
University of Iowa and Holden Comprehensive Cancer Center

Phenotyping the ccRCC TME to identify therapeutic strategies

A. Ari Hakimi, MD
Memorial Sloan Kettering Cancer Center

Targeting the Adenosine Pathway as Another Immune Checkpoint in Renal Cell Carcinoma

Lawrence Fong, MD
University of California, San Francisco

Session Four: General

Moderators: Peter Black, MD, FACS, FRCSC and William Kim, MD

The Abscopal Effect Untangled

Kent W. Mouw, MD, PhD
Dana-Farber Cancer Institute/Brigham & Women’s Hospital, Harvard Medical School

The Microbiome as an Immune Regulator

Karen S. Sfanos, PhD
Johns Hopkins University


Please login or register to take this course.